Orchestra BioMed Announces Participation in Investor Events
Upcoming Investor Conferences
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO), a pioneering biomedical company, is set to participate at several key investor conferences that promise to underscore its commitment to advancing high-impact medical technologies. These conferences present a unique opportunity for the company's leadership to connect with investors and share insights on future directions.
Conference Schedule
TD Cowen Annual Healthcare Conference
The first event on the calendar is the TD Cowen 45th Annual Healthcare Conference, scheduled for March 3, 2025. During this conference, company representatives will engage in a corporate presentation that begins at 2:30 PM ET. This presentation will not only highlight Orchestra BioMed's latest developments but also illustrate its strategic vision moving forward. Furthermore, a live audio webcast of this session will be available for those unable to attend in person, ensuring that all interested parties can access the presentation. The webcast can be accessed through the Investors section of the company’s website.
Barclays Annual Global Healthcare Conference
Following the TD Cowen event, Orchestra BioMed will also be featured in a Fireside Chat format at the Barclays 27th Annual Global Healthcare Conference on March 13, 2025, slated for 8:00 AM ET. This informal discussion aims to foster an engaging dialogue around the company’s recent advancements and future strategies.
One-on-One Investor Meetings
In addition to these presentations, the company will host one-on-one meetings with investors during the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. These private meetings offer a more personalized setting for investors to engage with the management team and discuss specific interests in the company.
Innovation at Orchestra BioMed
Orchestra BioMed is dedicated to accelerating the delivery of cutting-edge biomedical technologies through partnerships with leading medical device firms. With a focus on shared-risk reward models, the company strives to bring forth innovative healthcare solutions that address significant health challenges globally. Among its notable initiatives is the atrioventricular interval modulation (AVIM) therapy, aimed at treating hypertension, a major health concern. The company is also advancing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to tackle atherosclerotic artery disease, a leading cause of death worldwide.
Strategic Collaborations
To boost its development efforts, Orchestra BioMed has established critical collaborations with significant medical technology organizations. This includes a strategic partnership with Medtronic, which facilitates the advancement of AVIM therapy targeted at pacemaker-indicated patients. Additionally, a key alliance with Terumo underlines the commitment to commercializing the Virtue SAB for artery disease treatment. Such collaborative efforts epitomize the company’s strategic approach to innovate and enhance patient outcomes through effective technology integration.
Contact Information
For more information, potential investors can visit the company’s official website, where they can find insights about upcoming events, press releases, and detailed company information. Interested parties can also reach out to the company representatives directly: Jeremy Feffer from LifeSci Advisors is available for investor inquiries, while Kelsey Kirk-Ellis can be contacted for media-related questions.
Frequently Asked Questions
What is Orchestra BioMed known for?
Orchestra BioMed is a biomedical innovation company specializing in developing advanced technologies for treating significant health challenges, such as hypertension and artery disease.
When will Orchestra BioMed present at the TD Cowen Conference?
The company will present at the TD Cowen Annual Healthcare Conference on March 3, 2025, at 2:30 PM ET.
How can investors access the live webcast of the presentation?
The live webcast can be accessed through the Investors section of Orchestra BioMed's official website during the presentation time.
What other conferences will Orchestra BioMed participate in?
In addition to the TD Cowen Conference, the company will also be involved in the Barclays Annual Global Healthcare Conference on March 13, 2025.
What are Orchestra BioMed's main products?
The company is known for its AVIM therapy for hypertension and the Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.